Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Bulletin from the annual general meeting in Sedana Medical AB (publ)
Regulatory
Today, the annual general meeting of Sedana Medical AB (publ) (SEDANA: FN Stockholm) was held. In or…
Sedana Medical AB Interim report January-March 2022
Regulatory
First patient enrolled in US clinical program
Sedana Medical announces enrolment of first patient in US clinical program
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the first patient has been enro…
Financial Calendar
| Handelsbanken Nordic MidSmall Cap Seminar | 08 June 2022 | 09:10 |
| Interim report Q2 2022 | 21 July 2022 | 07:00 |
